Anthropic Unveils Claude Science AI for Research

Anthropic unveiled Claude Science, a specialized version of its Claude AI model, at its "The Briefing: AI for Science" event in San Francisco on June 30, 2026. This new model is designed to accelerate scientific research and is now available in beta. The event featured a demonstration of Claude Science by Alexander Tarashansky, who led its development.

During the event, Anthropic CEO Dario Amodei discussed his earlier prediction from an October 2024 essay, "Machines of Loving Grace," where he posited that AI could compress 50-100 years of biological and medical progress into 5-10 years, a concept he termed the "compressed 21st century." While Amodei clarified that this accelerated progress might not occur in the immediate next few years, he suggested it could manifest within the next decade, emphasizing Anthropic's commitment to achieving this scientific acceleration.

The event also included panel discussions featuring prominent figures from the pharmaceutical and biotech industries. Participants included Lotte Knudsen, a pioneer in GLP-1 drugs, Chris Boerner, CEO of Bristol Myers Squibb, Vas Narasimhan, CEO of Novartis, and Aviv Regev, Executive VP at Genentech. These discussions explored the potential of AI in scientific advancement, particularly in areas like drug discovery, while also acknowledging the limitations of current AI capabilities.

Despite the overall optimism, the conversations highlighted the nuanced reality of AI's role in science. The participants engaged in substantive dialogue, recognizing that even advanced AI systems have constraints and cannot solely drive progress in complex fields. The event, held at San Francisco's Yerba Buena Center, aimed to showcase Anthropic's vision and ongoing work towards leveraging AI for scientific breakthroughs.